TY - JOUR
T1 - Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia
AU - for the Kanto Study Group for Cell Therapy (KSGCT)
AU - Motohashi, Kenji
AU - Fujisawa, Shin
AU - Doki, Noriko
AU - Kobayashi, Takeshi
AU - Mori, Takehiko
AU - Usuki, Kensuke
AU - Tanaka, Masatsugu
AU - Fujiwara, Shinichiro
AU - Kako, Shinichi
AU - Aoyama, Yasuyuki
AU - Onoda, Masahiro
AU - Yano, Shingo
AU - Gotoh, Moritaka
AU - Kanamori, Heiwa
AU - Takahashi, Satoshi
AU - Okamoto, Shinichiro
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p =.01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p =.01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
KW - Cytogenetics
KW - allogeneic
KW - chronic myelomonocytic leukemia
KW - hematopoietic stem transplantation
KW - prognosis
KW - scoring system
UR - http://www.scopus.com/inward/record.url?scp=85031490839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031490839&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1387913
DO - 10.1080/10428194.2017.1387913
M3 - Article
C2 - 29032731
AN - SCOPUS:85031490839
VL - 59
SP - 1332
EP - 1337
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 6
ER -
